Beyond the barrier: unraveling the mechanisms of immunotherapy resistance
Immune checkpoint blockade (ICB) induces a remarkable and durable response in a subset
of cancer patients. However, most patients exhibit either primary or acquired resistance to …
of cancer patients. However, most patients exhibit either primary or acquired resistance to …
Innovative strategies of reprogramming immune system cells by targeting CRISPR/Cas9-based genome-editing tools: a new era of cancer management
The recent developments in the study of clustered regularly interspaced short palindromic
repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome …
repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome …
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
T cells are often absent from human cancer tissues during both spontaneously induced
immunity and therapeutic immunotherapy, even in the presence of a functional T cell …
immunity and therapeutic immunotherapy, even in the presence of a functional T cell …
Attenuated effector T cells are linked to control of chronic HBV infection
K Heim, Sagar, Ö Sogukpinar, S Llewellyn-Lacey… - Nature …, 2024 - nature.com
Hepatitis B virus (HBV)-specific CD8+ T cells play a dominant role during acute-resolving
HBV infection but are functionally impaired during chronic HBV infection in humans. These …
HBV infection but are functionally impaired during chronic HBV infection in humans. These …
Cancer-associated fibroblast spatial heterogeneity and EMILIN1 expression in the tumor microenvironment modulate TGF-β activity and CD8+ T-cell infiltration in …
CK Honda, S Kurozumi, T Fujii, D Pourquier… - …, 2024 - pmc.ncbi.nlm.nih.gov
Rationale: The tumor microenvironment (TME) and its multifaceted interactions with cancer
cells are major targets for cancer treatment. Single-cell technologies have brought major …
cells are major targets for cancer treatment. Single-cell technologies have brought major …
Preclinical models for drug discovery for metastatic disease
Despite many advances, metastatic disease remains essentially uncurable. Thus, there is an
urgent need to better understand mechanisms that promote metastasis, drive tumor …
urgent need to better understand mechanisms that promote metastasis, drive tumor …
Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies
JH Lo, R Agarwal, LW Goff, TR Heumann - Cancers, 2023 - mdpi.com
Simple Summary Biliary tract cancers (BTCs), comprising cancers of the bile ducts
(cholangiocarcinoma) as well as gallbladder cancers, continue to be challenging to treat …
(cholangiocarcinoma) as well as gallbladder cancers, continue to be challenging to treat …
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease
Hepatocellular carcinoma (HCC) frequently recurs from minimal residual disease (MRD),
which persists after therapy. Here, we identified mechanisms of persistence of residual …
which persists after therapy. Here, we identified mechanisms of persistence of residual …
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial
Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway
improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b …
improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b …
68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer
K Li, W Liu, H Yu, J Chen, W Tang, J Wang, M Qi… - The Journal of clinical …, 2024 - jci.org
BACKGROUND Improving and predicting tumor response to immunotherapy remains
challenging. Combination therapy with a transforming growth factor-β receptor (TGF-βR) …
challenging. Combination therapy with a transforming growth factor-β receptor (TGF-βR) …